At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 167 enrolled
Drug / intervention
Eltrombopag olaminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
In Brief
A Phase 4 clinical trial evaluating Eltrombopag olamine for Purpura, Thrombocytopaenic, Idiopathic. Completed, enrolled 167 participants across 34 sites in 11 countries.
Detailed Summary
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPurpura, Thrombocytopaenic, Idiopathic
CountriesCzechia, France, Germany, Hong Kong, Hungary, India, Italy, Pakistan, Russia, South Korea, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionMay 2014
TodayJul 2026
First PostedApr 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.3 years ago
Interventions
Eltrombopag olaminedrug
Thrombopoietin receptor agonist